| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 2.9 Billion |
| Market Size in 2026 | USD 3.2 Billion |
| Market Size by 2032 | USD 6.0 Billion |
| Projected CAGR | 11% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Semi-Consolidated |
Explore the market potential with our data-driven report
The companion animal diagnostics market size was USD 2.9 billion for 2025, and it will grow by 11.0% during 2026–2032, to reach USD 6.0 billion by 2032.
This is due to the increasing number of animals being adopted as pets globally and the growing trend of pet owners treating pets as family members, leading to the global trend of pet parenting. According to the American Pet Products Association (APPA), approximately 95 million U.S. households owned at least one pet in 2025, reflecting the expanding companion animal population and sustaining demand for routine and preventive diagnostic testing. In addition, the longer lifespan of companion animals is also one of the key factors driving the market. According to the Federation of European Companion Animal Veterinary Associations, the life expectancy of companion animals is increasing and they are living longer and healthier lives than a decade before. Risks of health problems like liver disease, cancer, senility, and joint disease increase with age. To counter these risks, the need for animal diagnostics is rising.
Furthermore, the growing adoption of advanced technologies such as big data, machine learning, and portable point-of-care (POC) instruments enables the analysis of diagnostic records from millions of animals to identify the early stages of chronic diseases, thereby improving veterinary diagnostic capabilities. For instance, the World Organisation for Animal Health (WOAH) develops international standards for disease prevention, surveillance, veterinary public health, and animal welfare. These standards support stronger veterinary healthcare systems and encourage wider adoption of diagnostic testing for early disease detection and control.
Veterinary diagnostics is undergoing a structural shift from single-analyte manual testing toward automated, AI-assisted, and molecular platforms capable of delivering same-visit results. Point-of-care hematology analyzers and cartridge-based PCR systems are increasingly complementing traditional reference laboratory workflows for many infectious and hematologic conditions, reducing turnaround times and enabling faster clinical decision-making. The Centers for Disease Control and Prevention's One Health Office highlights integrated human, animal, and environmental disease surveillance for the early detection of zoonotic pathogens. This growing focus on disease surveillance is supporting wider adoption of molecular and multiplex diagnostic technologies in veterinary laboratories.
In India, the Indian Council of Agricultural Research (ICAR)-National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI) uses artificial intelligence and machine learning models through its NADRES V2 platform, which provides monthly disease risk forewarnings for 15 economically important animal diseases. This capability highlights the growing adoption of advanced digital technologies in veterinary diagnostics and disease surveillance. The transformation is expected to continue as artificial intelligence-based image and cellular analysis tools expand beyond hematology into cytology and histopathology workflows. In May 2026, IDEXX Laboratories expanded its Fecal Dx antigen testing platform to include the detection of taeniid tapeworm species, including Taenia and Echinococcus, thereby broadening in-clinic parasitology screening capabilities for dogs and cats.
Rising incidence of zoonotic and vector-borne infections in companion animals is encouraging veterinary practices to expand routine and confirmatory diagnostic testing rather than relying solely on clinical presentation. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) oversees the licensing of veterinary diagnostic products, providing a regulatory framework that supports the availability of new immunodiagnostic and molecular test kits for companion animal diseases. As veterinarians increasingly incorporate diagnostic testing into preventive healthcare and wellness visits, demand for routine diagnostic procedures continues to grow across both dog and cat populations.
According to the American Veterinary Medical Association (AVMA), 74.2% of U.S. dog owners and 57.3% of cat owners reported visiting a veterinarian in 2024. This visitation rate reflects sustained demand for preventive veterinary care and diagnostic services. IDEXX Laboratories launched the IDEXX Cancer Dx panel in January 2025, a blood-based screening test designed for the early detection of canine lymphoma during routine wellness examinations. This launch highlights continued innovation in companion animal diagnostics. The adoption of multiplex diagnostic panels capable of simultaneously detecting multiple pathogens is expected to continue expanding, further integrating diagnostics into routine veterinary practice.
Diagnostic testing capacity remains constrained in many geographies by an uneven distribution of veterinary professionals outside major metropolitan areas. Workforce shortages continue to present operational challenges for broader adoption of advanced diagnostic platforms. Smaller and rural veterinary practices often lack the technical expertise, financial resources, and patient volumes needed to justify investment in molecular diagnostic systems, digital imaging platforms, and point-of-care analyzers. Limited availability of veterinarians and trained laboratory personnel also reduces the frequency of preventive health examinations and delays disease diagnosis. This shortage restricts the utilization of diagnostic tests despite increasing pet ownership and awareness of animal health.
Longer appointment wait times and limited access to specialized veterinary services can discourage routine screening and follow-up testing in underserved regions. Although workforce development initiatives are helping address shortages in some markets, limited access to skilled veterinary professionals continues to restrain the adoption of advanced companion animal diagnostic technologies and moderate overall market growth.
The growing adoption of pet insurance is expanding access to advanced veterinary diagnostics by reducing financial barriers for pet owners. Continued growth in insurance coverage presents significant opportunities for diagnostic test utilization. The North American Pet Health Insurance Association (NAPHIA) reports that 7.03 million pets were insured in North America at the end of 2024. This total represented a 12.2% increase from 2023. Pet insurance penetration reached nearly 4% of dogs and cats combined. The industry also generated USD 5.2 billion in written premiums during 2024, reflecting continued expansion of the pet insurance market.
As pet insurance reduces out-of-pocket veterinary expenses, insured pet owners are generally more likely to pursue veterinarian-recommended diagnostic testing, increasing utilization of advanced diagnostic services. This opportunity is expected to expand as employer-sponsored pet insurance benefits and regulatory initiatives improve insurance accessibility and transparency.
The immunodiagnostics category holds the largest market share of 40% in 2025. This can be ascribed to the surging adoption of diagnostic products based on immunodiagnostic technology and advanced immunoassay tests. These tests offer high sensitivity, specificity, and rapid turnaround times, making them highly preferred by veterinary practitioners for routine disease screening in companion animals. Moreover, the U.S. FDA's Veterinary Laboratory Investigation and Response Network (Vet-LIRN), a partnership with 48 veterinary diagnostic laboratories across North America, supports companion animal disease investigations and antimicrobial resistance surveillance, strengthening veterinary diagnostic infrastructure and the adoption of advanced diagnostic testing. In addition, increasing investment in companion animal disease surveillance continues to support the widespread use of immunodiagnostic testing.
The molecular diagnostics category will have the highest CAGR of approximately 11.5%, driven by the increasing adoption of PCR-based assays, multiplex molecular panels, and genomic technologies, which enable rapid and accurate pathogen detection in companion animals. Research published through the National Center for Biotechnology Information highlights the expanding application of whole-genome sequencing to characterize antimicrobial resistance in clinical isolates from companion animals. This research reflects continued advancements in molecular diagnostic technologies and veterinary infectious disease surveillance. The growing availability of multiplex assays and point-of-care PCR platforms in veterinary clinics is expected to support the expansion of this category.
The technologies analyzed in this report are:
The dog category holds the larger market share in 2025, due to the increasing population and adoption rate of dogs and the rising cases of zoonotic diseases in the world, which lead to the surging demand for veterinary visits and diagnostics for dogs. Dogs account for a higher volume of veterinary visits and diagnostic testing due to their greater utilization of preventive healthcare services and routine wellness examinations. Vaccination programs and screening for infectious, parasitic, and chronic diseases are also contributing to this higher volume. According to the American Veterinary Medical Association's 2025 Pet Ownership and Demographics Sourcebook, the U.S. dog population reached 87.3 million in 2025. Dogs were present in 42.6% of U.S. households.
The cat category will have the higher CAGR of approximately 11.3%, driven by increasing adoption of pet cats, growing awareness of feline preventive healthcare and early disease diagnosis, and rising veterinary visits support the growth of this category. The expanding availability of feline-specific diagnostic tests for chronic kidney disease, hyperthyroidism, diabetes, and infectious diseases is reinforcing this segment. According to the American Veterinary Medical Association's 2025 Pet Ownership and Demographics Sourcebook, the U.S. cat population increased from 73.8 million in 2024 to 76.3 million in 2025.
The animal types analyzed in this report are:
The clinical pathology category holds the largest market share of 45% in 2025, due to the increasing cases of chronic diseases in companion animals. This category encompasses hematology, clinical chemistry, cytology, and coagulation testing that form the backbone of routine veterinary diagnostic workups. A 2024 IDEXX Laboratories study analyzing wellness laboratory results from 167,593 dogs and 54,211 cats confirms that routine biochemistry, hematology, and urinalysis frequently identified clinically relevant abnormalities, highlighting the importance of clinical pathology for early disease detection. It also supports the widespread adoption of routine diagnostic testing in companion animals.
The virology category will have the highest CAGR, driven by the increasing prevalence of viral infectious diseases in companion animals, rising awareness of zoonotic disease prevention and the growing adoption of rapid molecular and point-of-care diagnostic technologies. The expanding use of PCR-based assays, multiplex diagnostic panels, and rapid antigen tests is enabling earlier and more accurate detection of viral pathogens. This capability supports timely clinical decision-making, disease management, and infectious disease surveillance, while growing investment in preventive animal healthcare continues to drive the adoption of virology diagnostics.
The applications analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 40%, in 2025, due to the growing population of companion animals, especially in the U.S., the surging pet insurance, and the rising health expenditure on pets in the region. The region's leadership is reinforced by dense networks of veterinary hospitals and reference laboratories that have rapidly adopted point-of-care hematology and immunodiagnostic platforms, alongside broad pet insurance penetration that reduces out-of-pocket cost barriers to diagnostic testing.
Additionally, the U.S. is the largest country market within North America, driven by the widespread adoption of advanced diagnostic technologies in veterinary clinics. This position is further supported by a large base of accredited veterinary teaching hospitals and increasing demand for specialty and molecular diagnostic testing. According to the American Pet Products Association (APPA), the U.S. pet industry generated approximately USD 158 billion in expenditure in 2025, with spending on veterinary care and diagnostics continuing to increase alongside rising demand for preventive and specialized animal healthcare.
Asia-Pacific will have the highest CAGR of approximately 11.9%, due to the rising prevalence of various zoonotic diseases, the increasing awareness about animal health, and the surging income levels. Urbanization and the growing trend of pet humanization are encouraging pet owners to invest in preventive healthcare and routine diagnostic testing.
Governments across the region are undertaking initiatives to strengthen veterinary healthcare systems. These initiatives are also improving disease surveillance and preparedness for animal disease outbreaks. For instance, Japan continues to strengthen veterinary disease surveillance through its Ministry of Agriculture, Forestry and Fisheries (MAFF), while South Korea has enhanced digital animal disease monitoring through the Korea Animal Health Integrated System (KAHIS). Both programs are reinforcing the adoption of advanced diagnostic technologies across the region. As veterinary infrastructure continues to expand and international and domestic companies strengthen their presence in the region, market participants are expected to benefit from significant growth opportunities and reinforce their competitive position over the forecast period.
China represents the largest country market within Asia-Pacific, driven by a rapidly expanding urban pet population, changing demographic patterns, and increasing willingness among younger pet owners to invest in advanced veterinary care. The country's diagnostics demand is further supported by continued modernization of the veterinary healthcare sector and increasing availability of advanced diagnostic products. According to the U.S. Department of Agriculture's Foreign Agricultural Service (USDA FAS), China's urban pet population reached 124.1 million in 2024. This total comprised 52.6 million dogs and 71.5 million cats, representing year-over-year increases of 1.6% and 2.5%, respectively.
These regions and countries are analysed:
The market is semi-consolidated, with a limited number of multinational companies accounting for a significant share of global revenue, while numerous regional and specialized players compete in niche segments. Leading companies including IDEXX Laboratories, Zoetis, Thermo Fisher Scientific, and bioMerieux benefit from broad product portfolios, proprietary analyzer-and-reagent ecosystems, extensive veterinary reference laboratory networks, and long-standing relationships with veterinary hospitals and clinics. Recurring consumables revenue and strong brand recognition create high barriers to entry. Regulatory expertise and continuous investment in research and development are reinforcing these barriers. Regional manufacturers and niche providers remain competitive in areas such as molecular diagnostics, point-of-care testing, diagnostic imaging, and immunodiagnostics in emerging markets. This competitive landscape enables established companies to maintain market leadership while allowing specialized players to compete through technological innovation and regional expertise.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages